UNSPSC 51411705: Pentifylline

This classification denotes a phosphodiesterase inhibitor and antiplatelet agent with the molecular formula C13H20N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MBM1C4K26S, chemically known as 3,7-dimethyl-1-hexyl-1h,3h-purin-2,6-dione but generally known as pentifylline, which bears US NIH Compound Identifier 70569. European Medicines Agency schedules Pentifylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09694MIG.

UNSPSC 51411705 Pentifylline is a Commodity code covering the supply of specific pharmaceutical products used by emergency medical services, health systems, and state pharmacy benefit programs. State and local governments procure pentifylline and related advanced life support medications through direct-supply contracts with pharmaceutical manufacturers and authorized wholesalers to support fire rescue operations, hospital formularies, and Medicaid pharmacy benefit management. The issuing bodies span municipal fire departments, state health agencies, and multistate cooperative purchasing alliances. City of Tampa's Purchasing Department, the Texas Health and Human Services Commission, and the Minnesota Department of Administration (administering the Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP) have recently posted opportunities in this space, reflecting activity across city procurement offices and state-level pharmacy programs.

Recent opportunities show activity concentrated in the South and Midwest, anchored by Tampa, Florida; Texas; and Minnesota. The City of Tampa issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications including Labetalol HCI, Epinephrine, Adenosine, and Diltiazem to supply Tampa Fire Rescue, with a response deadline of April 8, 2026, and an estimated contract value of $40,000.00 featuring a 5 percent Small Local Business Enterprise sheltered-market bid discount. MMCAP issued an RFP (S1070000015802) on January 20, 2026, with a March 26, 2026 response deadline to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, requiring vendors to maintain relationships with three authorized wholesalers (Cencora, Cardinal Health, and Morris & Dickson) and comply with cGMP and Drug Supply Chain Security Act certification. Texas HHS posted a Request for Information (RFI No. HHS0017013) on April 3, 2026, exploring direct-to-manufacturer prescription programs with no formal award timeline or budget disclosed at the information-gathering stage. All solicitations require FDA compliance, Safety Data Sheets, comprehensive insurance coverage, and minimum shelf-life guarantees.